* Regents reaffirm nondiscrimination policy
   
* Diversity officers: Outreach, pipeline programs crucial for student recruitment
   
* Regents OK annual budget, hear warnings of looming financial challenges
   
* First class of Boettcher Investigators taking on cancer, Parkinson's, more
   
* Office of Policy and Efficiency's latest policy changes take effect Thursday
   
* Staff survey indicates wide-ranging opinions on hot topics
   
* Five questions for Doug Duncan
   
* Shakespeare Fest actors turn to words of Founding Fathers
   
* Clothing drive benefits job seekers, student scholarships
   
* Phoenix Center earns confidentiality pledge from campus leadership
   
* Conference to examine big questions of society's health, social issues
   
* Obituary: Patricia Morris
   
* Did you know?
   
* People
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
  CU-BOULDER
  Renovations to Andrews Hall cross finish line with LEED gold certification
 
  UCCS
  Legacy of Bill Daniels highlighted in special event
 
  UC DENVER
  Hundreds take part in Bike to Work Day
 
  ANSCHUTZ MEDICAL CAMPUS
  First-in-nation program focuses on anti-cancer stem cell therapies
 
  CU FOUNDATION
  Cancer Center pledge will promote needed research
 
  TECH TRANSFER
  Optioned device helps diagnose acid reflux, other esophageal diseases
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
Share your thoughts
   
  LETTERS TO THE EDITOR
Share your opinions

CONTACT US
Send your thoughts and suggestions for the Newsletter
   
   

News from the CU system - Anschutz Medical Campus

First-in-nation program focuses on anti-cancer stem cell therapies

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer — cancer stem cells (CSCs).

The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both at the University of Colorado School of Medicine.

"Through the CCTP, we believe we can change the way most cancers are treated by targeting tumor-initiating cells as opposed to conventional therapies that address the bulk of the tumor," said Antonio Jimeno, M.D., Ph.D., program director and head and neck cancer specialist. "We hope that by targeting the cancer stem cells we can bring solid tumor cure rates in line with those for some blood cancers — upwards of 75 percent, although our ultimate goal is 100 percent."

Jimeno will direct the new program with senior co-directors Dennis Roop, Ph.D., Gates Stem Cell Center director and professor of dermatology at the medical school, and S. Gail Eckhardt, M.D., UCCC deputy director, head of medical oncology at the medical school and leader of UCCC's renowned early phase cancer clinical trials program.

Although CSCs may make up less than 0.1 percent of the tumor, they have a big effect. They're the ones that accumulate DNA damage from sun exposure, tobacco use and other carcinogens, Roop said. Many cancer scientists believe CSCs initiate and maintain cancers, just as normal stem cells maintain normal tissues.

CSCs are different from the cells that make up a tumor's bulk. They are generally impervious to chemotherapy and radiation, and perhaps even new "targeted" therapies. And because CSCs can weather the storm of traditional cancer treatment, many cancer scientists believe they are primarily responsible for cancer recurrence.

"We've already had success in early clinical trials with some drugs that happen to be cancer stem cell-targeting drugs," Jimeno said. "I have patients who are essentially in remission after a year with few side effects."

New treatments the program identifies will likely be complex because they will combine conventional therapies and CSC-targeted drugs. That complexity will require new tools for assessing tumors and blood samples, as well as scaled-down genetic tests that are analyzed by modern bioinformatics tools — none of which are available for clinical trials at most centers.

"I hope that in the near future, we can take a tiny sample of a patient's tumor, do a quick test to see which stem cell targets are active, and quickly come up with a cocktail of drugs that will kill the root of the tumor with fewer side effects to the patient," Jimeno said. "We think this process will truly address the complexities of cancer."

The CCTP, which includes experts in basic cancer research, imaging and bioinformatics, also will design these tests and tools.

"We have the incredible talent and infrastructure in place to build a program around an entirely new way of treating cancer," Roop said. "We have all the required scientific and clinical investigators and extraordinary new technologies in place to do the basic science research and move new treatments quickly to patients."

The program will concentrate on running clinical trials of anti-CSC drugs, and assessing the impact on CSCs, Jimeno said.

"Many pharmaceutical companies are developing anti-CSC drugs right now," he said, "and our program is a platform that will offer possibilities they may not yet be aware exist for clinical applications. We have the patients, tools and infrastructure that no other center in the United States has."

Roop said that creating a hub of cancer stem cell research in Colorado will bring economic dividends to the state, just as the Gates Stem Cell Center has. Since 2007, that center has grown to 62 full-time employees and received $29 million in research funding with an additional $20 million pending — a rate of about 20 percent annual growth in terms of research dollars, faculty members and staff.

"Just by building this program, we will be able to attract top talent to our campus, and they will bring their millions of research dollars and new high-paying jobs with them," he said. "This will also have an immediate impact on the University of Colorado Hospital, where patients are treated, as we bring new anti-CSC drugs into testing. But the best news is that through doing this, we believe we will find treatments that kill the cancer without almost killing the patient."

What's different about the CCTP:

  • A clinical trials program focused on developing tools for quickly understanding the impact of candidate anti-cancer stem cell drugs and incorporating them into a clinical setting.
  • A collaboration between a National Cancer Institute-designated comprehensive cancer center and a well-funded stem cell center, both of which have rich scientific and technological infrastructure in place to take this new approach to clinical trials.
  • An integrated, multidisciplinary faculty roster that includes clinical and research experts from medical oncology, surgery, radiation oncology, dermatology, cancer biology and bioinformatics, among others. This team composition will prove to be the fastest route to bring successful treatments to patients.
  • Dedicated to collaboration over competition, UCCC and the Gates Stem Cell Center are known for forging successful partnerships with others regardless of what school, program or particular medical area they may work in.
  • Pairs of advanced animal models of three major cancer types — melanoma, squamous skin cancer and head and neck cancer — developed by teams of Colorado scientists and other advanced technologies will give scientists and doctors cutting-edge tools to rapidly understand how new drugs selectively target CSCs for destruction.
Bookmark - Print - Share
 
Previous Anschutz Medical Campus Stories

06/16/2010
UCH receives prestigious nursing designation

06/02/2010
University of Colorado Hospital moves forward with $400 million expansion

05/26/2010
Cancer patients win big as governor signs patient access bills into law

05/12/2010
Study: Many pregnant women not getting enough vitamin D

05/05/2010
Breakthrough treatment extends lives of prostate cancer patients

04/28/2010
Some pediatric brain tumors might be worsened by immune gene expression

04/21/2010
School of Medicine, partners will work to prevent mistreatment of children

04/14/2010
University of Colorado Hospital provides funding for new crisis services system

04/07/2010
University of Colorado Cancer Center researchers receive $3.5 million grant

03/31/2010
Hospital receives distinguished designation for excellence in nursing

03/24/2010
Regional stem-cell center launched by School of Medicine

03/17/2010
School of Medicine program receives oral health grant

03/10/2010
UC Denver one of top places for postdocs to work

03/03/2010
University of Colorado Hospital internal medicine, specialty clinic relocating

02/24/2010
New type of complex genetic variation discovered

02/17/2010
UC Denver announces state's first bioengineering department

02/10/2010
School of Dental Medicine gives kids a smile

02/03/2010
Emergency medicine physicians take part in suicide research trial

01/27/2010
Researchers receive grant to study impact of law on public health practice

01/20/2010
Assembling planet's Tree of Life less daunting thanks to researchers

01/13/2010
State-of-the-art imaging offers enhanced treatment for arrhythmia

01/06/2010
Rural medicine, Down syndrome programs receive federal support

12/16/2009
Study highlights lack of knowledge regarding hospital medications

12/09/2009
School of Pharmacy researcher receives funding from Michael J. Fox Foundation

12/02/2009
New UC Denver program puts high school grads on pathway to med school

11/18/2009
Award of $577,000 will aid study of tuberculosis treatment

11/11/2009
Depression Center works to establish national network

11/04/2009
School of Medicine to take part in nationwide study of blood pressure

10/28/2009
College of Nursing expands offerings in Western Regional Graduate Program

10/21/2009
Study: Tanning associated with moles in very light-skinned children

10/14/2009
When the laboratory meets the studio

10/07/2009
When the laboratory meets the studio

09/30/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/23/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/16/2009
University of Colorado Cancer Center wins National Cancer Institute grant

09/02/2009
Ground broken on planned VA medical center

08/19/2009
SOM, state labor department to manage training facility

08/06/2009
Pulmonary hypertension drug helps former smokers

07/23/2009
Breast cancer researcher receives gift from Avon